
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is a leading gene therapy company with a robust pipeline that includes programs for various devastating diseases such as hemophilia, Huntington's disease, and cardiovascular diseases. With promising data from its AMT-260 trial in refractory epilepsy patients and positive regulatory updates for its AMT-130 program, the company is making significant progress towards its goal of commercializing gene therapies. While there are risks involved, including clinical development, commercialization, and pricing risks, uniQure's strong financials, and ongoing research programs make it a promising stock to invest in.
Bears say
uniQure is currently facing timing risks for its gene therapy program, AMT-130, due to potential delays in the regulatory process. There is also the risk of competition from other gene therapy companies with similar treatments in development. Additionally, the company's financials could be negatively impacted by any potential clinical trial failures or setbacks, and its valuation may be too high given the uncertainties surrounding its pipeline.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares